Pancreatic Cancer Research

ResearcherUniversity of CincinnatiActive in the last 2 years

Syed Ameen Ahmad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6179-5252; OpenAlex author ID A5091876744. Sources: OpenAlex.

Their work

Papers
42 (first author 6, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
147
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 3 papers · 2014: 3 papers · 2015: 2 papers · 2016: 4 papers · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 5 papers · 2022: 5 papers · 2023: 3 papers · 2024: 5 papers · 2025: 4 papers

Papers 42

  1. Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.70130↗
  2. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  3. Large language models as clinical decision support tools: A call for careful implementation in the care of patients with pancreatic cancer. First author DOI 10.1016/j.surg.2025.109378↗
  4. Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.1097/xcs.0000000000001277↗
  5. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. Co-author DOI 10.1016/j.gassur.2023.12.022↗
  6. Neoadjuvant and Adjuvant Therapy in Resectable Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.suc.2024.04.002↗
  7. Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A02150… Co-author DOI 10.1245/s10434-024-15670-6↗
  8. Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment. Co-author DOI 10.3389/fonc.2024.1402128↗
  9. Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. Last author DOI 10.6004/jnccn.2023.7099↗
  10. Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ductal adenocarcinoma cells in vitro and in v… Co-author DOI 10.1007/s00109-023-02290-y↗
  11. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancr… Co-author DOI 10.1245/s10434-022-12741-4↗
  12. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  13. Radiation therapy in borderline resectable pancreatic cancer: A review. Last author DOI 10.1016/j.surg.2021.12.013↗
  14. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough? Co-author DOI 10.1245/s10434-022-11363-0↗
  15. Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.1245/s10434-022-11580-7↗
  16. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-instit… Co-author DOI 10.1245/s10434-022-11804-w↗
  17. Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunoc… Co-author DOI 10.3390/cancers14112618↗
  18. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2020.7328↗
  19. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment. Co-author DOI 10.1016/j.jss.2020.09.009↗
  20. A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer: Let the Data Speak. Last author DOI 10.1097/sla.0000000000004471↗
  21. The Landmark Series: Preoperative Therapy for Pancreatic Cancer. Last author DOI 10.1245/s10434-021-10075-1↗
  22. A First-In-Class, Humanized Antibody Targeting Alternatively Spliced Tissue Factor: Preclinical Evaluation in an Orthotopic Model of Pancreatic Ductal Adenocar… Co-author DOI 10.3389/fonc.2021.691685↗
  23. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2020.05.013↗
  24. Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Can… First author DOI 10.1097/mpa.0000000000001602↗
  25. Screening patients at high risk for pancreatic cancer-Is it time for a paradigm shift? Co-author DOI 10.1002/jso.25616↗
  26. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2019.01.061↗
  27. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  28. Equivalent Treatment and Survival after Resection of Pancreatic Cancer at Safety-Net Hospitals. Co-author DOI 10.1007/s11605-017-3549-0↗
  29. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Co-author DOI 10.1001/jamasurg.2016.1137↗
  30. A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for panc… First author DOI 10.1016/j.hpb.2015.11.009↗
  31. Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.7955↗
  32. Two studies pave the way for preoperative therapy in pancreatic cancer patients. First author PMID 28941435↗
  33. Reply to the letter to the editor regarding manuscript entitled: "Perioperative blood transfusion is associated with decreased survival in patients undergoing … First author DOI 10.1007/s11605-014-2705-z↗
  34. Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results. First author PMID 26552293↗
  35. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.28327↗
  36. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-ins… Last author DOI 10.1007/s11605-014-2567-4↗
  37. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  38. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Last author DOI 10.1245/s10434-013-2886-9↗
  39. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Co-author DOI 10.1245/s10434-013-2889-6↗
  40. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0075507↗
  41. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. Co-author DOI 10.1111/j.1477-2574.2011.00432.x↗
  42. Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer. Co-author DOI 10.1007/s11605-011-1448-3↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sameer H. Patel · 13 shared papers, 2019–2025 · strength 1.83
  2. Gregory C. Wilson · 10 shared papers, 2014–2023 · strength 1.32
  3. Matthew H. G. Katz · 10 shared papers, 2013–2024 · strength 1.08
  4. Nipun B. Merchant · 9 shared papers, 2012–2025 · strength 0.99
  5. Davendra P. S. Sohal · 6 shared papers, 2021–2024 · strength 0.98
  6. Kevin M. Turner · 4 shared papers, 2022–2025 · strength 0.98
  7. Shishir Kumar Maithel · 8 shared papers, 2014–2025 · strength 0.97
  8. Daniel Erik Abbott · 8 shared papers, 2013–2025 · strength 0.85
  9. Olugbenga Olanrele Olowokure · 6 shared papers, 2020–2022 · strength 0.79
  10. Jordan R. Kharofa · 5 shared papers, 2020–2022 · strength 0.69
  11. David A. Kooby · 8 shared papers, 2011–2025 · strength 0.67
  12. Alexander A. Parikh · 6 shared papers, 2012–2025 · strength 0.64
  13. Jashodeep Datta · 4 shared papers, 2021–2025 · strength 0.62
  14. Rebecca Anne Snyder · 3 shared papers, 2023–2025 · strength 0.57
  15. Robert C.G. Martin · 8 shared papers, 2011–2025 · strength 0.55
  16. Elena Gabriela Chiorean · 3 shared papers, 2021–2024 · strength 0.54
  17. Chet W. Hammill · 3 shared papers, 2022–2025 · strength 0.47
  18. Jordan M. Cloyd · 2 shared papers, 2024–2025 · strength 0.47
  19. Andrew M. Lowy · 4 shared papers, 2013–2024 · strength 0.38
  20. Philip A. Philip · 4 shared papers, 2013–2024 · strength 0.38
  21. Sharon Marie Weber · 6 shared papers, 2011–2025 · strength 0.37
  22. Charles Raben Scoggins · 6 shared papers, 2011–2025 · strength 0.37
  23. Ryan P. Johnson · 1 shared paper, 2024 · strength 0.36
  24. Paul H. McClelland · 1 shared paper, 2024 · strength 0.36
  25. Hong Joo Kim · 3 shared papers, 2019–2023 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.